Special Reports

After-Hours Movers 2/9: MCZ, NTGR, CYBI, BIDU, RMTR, FNSR Higher; QUIK, LGF, APPY, VRUS, EXBD Lower Feb 9, 2010 05:40PM

Mad Catz Interactive Inc. (NYSE: MCZ) 36% HIGHER; reports Q3 EPS of $0.09, compared to ($0.49) in the same quarter last year. Revenue for the quarter was $48.8 million, versus $40.8 million in Q309.

QuickLogic Corp. (NASDAQ: QUIK) 14.4% LOWER; reports Q4 adj-loss of $0.04. Revenue for the quarter was $4.3 million, versus $4.28 million in Q408.

NETGEAR, Inc. (NASDAQ: NTGR) 14.3% HIGHER; reports Q4 EPS of $0.34, 12 cents better than the analyst estimate of $0.22. Revenue for the quarter was $218.8 million, which compares to the estimate of $178.36 million. NETGEAR sees Q1 sales of $195-$205 million, versus the consensus of $175.8 million.

Cybex International Inc. (NASDAQ: CYBI) 14% HIGHER; reports Q4 EPS of $0.06, 3 cents better than the analyst estimate of $0.03. Revenue for the quarter was $34.80 million, which compares to the estimate of $33.55 million.

Baidu (NASDAQ: BIDU) 9.1% HIGHER; reports Q4 EPS of $1.99, 20 cents better than the analyst estimate of $1.68. Revenue for the quarter was $184.7 million, which compares to the estimate of $180.02 million. Sees Q1 sales of $176-$181 million, versus the consensus of $170.23 million.

Ramtron International Corp. (Nasdaq: RMTR) 8.7% HIGHER; reports Q4 EPS of $0.03, compared to $0.03 in the same quarter last year. Revenue for the quarter was $13.3 million, which compares to the estimate of $11.03 million.

Finisar Corporation (NASDAQ: FNSR) 7% HIGHER; issues prelim. Q3 sales: $166-$167 million, versus the consensus of $155.6 million. The company previously guided sales to $148-$158 million.

Lions Gate Entertainment (NYSE: LGF) 5.8% LOWER; reports Q3 loss of ($0.55), versus the analyst estimate of ($0.23). Revenue for the quarter was $371.5 million, which compares to the estimate of $353.44 million.

AspenBio Pharma, Inc. (NASDAQ: APPY) 5.8% LOWER; today reported conclusions from its pre-planned, independent, interim analysis of the Company's ongoing supplemental clinical trial of AppyScore, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outlined next steps for its AppyScore 510(k) filing with the U.S. Food and Drug Administration (FDA). Based on the interim analysis, the trial, currently with over 600 patients enrolled, will continue enrollment to approximately 800 patients with completion anticipated in March of 2010. Given the time estimate to complete the current trial and related data analysis, the Company has withdrawn its 510(k) on file with the FDA and will submit a new 510(k) with full results from the ongoing clinical trial. This clinical trial is statistically sized to stand alone and thereby becomes the pivotal trial to support the new 510(k) submission.

Pharmasset, Inc. (Nasdaq: VRUS) 5.4% LOWER; reports Q4 loss of $0.49, versus the analyst estimate of ($0.43). Revenue for the quarter was $300,000, which may not compare to the estimate of $1.77 million.

Tessera Technologies Inc. (NASDAQ: TSRA) 5.1% HIGHER; will replace Financial Federal Corp. (NYSE: FIF) in the S&P SmallCap 600 index after the close of trading on Thursday, February 18.

Corporate Executive Board Company (NASDAQ: EXBD) 5% LOWER; reports Q4 EPS of $0.40, ex-items, versus the analyst estimate of $0.24. Revenue for the quarter was $108 million, which compares to the estimate of $101.33 million. Sees FY10 adj-EPS of $0.85-$1.10, versus the consensus of $1.29. Sees sales of $385-$405 million, which compares to the Street estimate of $418.21 million. Raises its quarterly dividend from $0.10 to $0.11.

Seattle Genetics (NASDAQ: SGEN) 4.9% HIGHER; reports a Q4 loss of $0.12, 11 cents better than the analyst estimate of ($0.23). Revenue for the quarter was $21.8 million, which compares to the estimate of $11.71 million. Seattle Genetics anticipates 2010 revenues will be in the range of $95 million to $105 million. These revenues are generated from fees, milestones and reimbursements earned through the companys brentuximab vedotin, dacetuzumab and ADC collaborations. Revenues are expected to include approximately $70 million related to the companys dacetuzumab collaboration that will end in June 2010, primarily related to cash amounts previously received. (Consensus is $47.32M)

Healthcare Services Group Inc. (NASDAQ: HCSG) 4.3% LOWER; reports Q4 EPS of $0.15, versus the analyst estimate of $0.20. Revenue for the quarter was $182.56 million, which compares to the estimate of $180.96 million.

Diodes Incorporated (NASDAQ: DIOD) 4.2% HIGHER; reports Q4 EPS of $0.36, 7 cents better than the analyst estimate of $0.29. Revenue for the quarter was $130.3 million, which compares to the estimate of $129 million. Sees Q1 sales of $131-$137 million, versus the consensus of $125.5 million.

Drugstore.com Inc. (Nasdaq: DSCM) 4% HIGHER; reports Q4 loss of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter was $ 117.4 million, which compares to the estimate of $108 million.

Barrett Business Services Inc. (Nasdaq: BBSI) 4% LOWER; reports Q4 EPS of $0.21, 1 cent better than the analyst estimate of $0.20. Revenue for the quarter was $62.6 million, versus the $64.63 million reported in the same quarter last year. Sees Q1 loss of $0.19-$0.22, versus the consensus of a loss of $0.06.

Alico Inc. (Nasdaq: ALCO) 3.6% LOWER; reports Q1 loss of $0.19, versus the analyst estimate of $0.12 and compared to a loss of $0.02 in the same quarter last year. Revenue for the quarter was $14.1 million, which compares to the estimate of $22.49 million.

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) 3.4% HIGHER; announced that the first patent covering the composition and method of use of Intermezzo (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent Application Serial No. 11/060,641, on December 14, 2009. The newly issued patent, U.S. Patent No. 7,658,945, titled "Compositions for Delivering Hypnotic Agents Across the Oral Mucosa and Methods of Use Thereof," will expire no earlier than February 2025.

Prospect Capital Corporation (NASDAQ: PSEC) 3.4% LOWER; reports Q2 EPS of $0.29, 2 cents better than the analyst estimate of $0.27. Net investment income was $16.93 million for the quarter, compared to $11.96 for the same period in 2008.

American Science and Engineering (NASDAQ: ASEI) 3.3% LOWER; reports Q3 EPS of $0.64, versus the analyst estimate of $0.98. Revenue for the quarter was $54.9 million, which compares to the estimate of $60.05 million. The company also approved a dividend of $0.30 per share of common stock, or $1.20 annualized.

Bob Evans Farms Inc. (Nasdaq: BOBE) 2.9% LOWER; reports Q4 EPS of $0.58, 2 cents below the analyst estimate of $0.60. Revenue for the quarter was $429.8 million, which compares to the estimate of $438 million. Reaffirms outlook.

Capstone Turbine Corporation (NASDAQ: CPST) 2.7% HIGHER; reports a Q3 loss of $0.04, 1 cent better than the analyst estimate of ($0.05). Revenue for the quarter was $16.0 million, which compares to the estimate of $17.34 million.

To get this report daily, visit http://www.streetinsider.com/entities/After-Hours+Movers.

Trading Radar for 02/10: Sprint (S), Dean Foods (DF), Scripps Networks (SNI), Vale S.A. (VALE), Level 3 Comm (LVLT) Report Feb 9, 2010 03:06PM

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:

Before Market Opens
Economics:
8:30am EST

• Trade Balance - Street sees ($35.8B)

Earnings:

ACCO Brands (NYSE: ABD) - consensus EPS $0.22
ArcelorMittal (NYSE: MT) - consensus EPS $0.27
Brookfield Homes Corporation (NYSE: BHS) - no Street consensus
Coca-Cola Enterprises Inc. (NYSE: CCE) - consensus EPS $0.21
Computer Sciences Corporation (NYSE: CSC) - consensus EPS $1.23
Dean Foods (NYSE: DF) - consensus EPS $0.37
Discovery Communications (NASDAQ: DISCA) - consensus EPS $0.36
Elan Corporation, plc (NYSE: ELN) - consensus loss $0.08
Forrester Research (NASDAQ: FORR) - consensus EPS $0.28
IntercontinentalExchange, Inc. (NYSE: ICE) - consensus EPS $1.14
L-1 Identity Solutions, Inc. (NYSE: ID) - consensus loss $0.01
Level 3 Communications (NASDAQ: LVLT) - consensus loss $0.10
Louisiana-Pacific Corp (NYSE: LPX) - consensus loss $0.19
Marsh & McLennan Companies, Inc. (NYSE: MMC) - consensus EPS $0.37
Net Serviços de Comunicação S.A. (NASDAQ: NETC) - consensus EPS $0.18
Scripps Networks Interactive Inc (NYSE: SNI) - consensus EPS $0.51
Sonoco Products (NYSE: SON) - consensus EPS $0.50
Sprint Nextel Corporation (NYSE: S) - consensus loss $0.19
The New York Times Company (NYSE: NYT) - consensus EPS $0.38
TransDigm Group Incorporated (NYSE: TDG) - consensus EPS $0.71
Wright Express Corporation (NYSE: WXS) - consensus EPS $0.54
Wyndham Worldwide (NYSE: WYN) - consensus EPS $0.37

Intraday or Not Specified:
Economics:
10:00am EST

• Crude Inventories - no Street consensus

2:00pm EST

• Treasury Budget - Street sees ($46B)

Earnings:

BHP Billiton PLC (NYSE: BHP) - no Street consensus
BioClinica, Inc. (NASDAQ: BIOC) - consensus EPS $0.06
CAE (NYSE: CAE) - no Street consensus
comScore, Inc. (NASDAQ: SCOR) - consensus EPS $0.04
Deltek Inc. (NASDAQ: PROJ) - consensus EPS $0.13
EastGroup Properties (NYSE: EGP) - consensus EPS $0.75
Equinix Inc. (NASDAQ: EQIX) - consensus EPS $0.34
GSI Commerce, Inc. (NASDAQ: GSIC) - consensus EPS $0.51
HNI Corporation (NYSE: HNI) - consensus EPS $0.24
Lionbridge Technologies (NASDAQ: LIOX) - consensus loss $0.01
National Research Corporation (NASDAQ: NRCI) - consensus EPS $0.29
OraSure Technologies, Inc. (NASDAQ: OSUR) - consensus loss $0.09
Protective Life Corporation (NYSE: PL) - consensus EPS $1.02
Sanofi-Aventis (NYSE: SNY) - no Street consensus
Sierra Wireless, Inc (NASDAQ: SWIR) - consensus EPS $0.18
Sigma-Aldrich Corporation (NASDAQ: SIAL) - consensus EPS $0.72

After Market Closes:
Earnings:

Activision Blizzard, Inc. (NASDAQ: ATVI) - consensus EPS $0.44
Amkor Technology, Inc. (NASDAQ: AMKR) - consensus EPS $0.09
AptarGroup (NYSE: ATR) - consensus EPS $0.47
ARRIS Group, Inc. (NASDAQ: ARRS) - consensus EPS $0.27
BioMed Realty Trust, Inc. (NYSE: BMR) - consensus EPS $0.31
Boston Scientific Corporation (NYSE: BSX) - consensus EPS $0.13
Copa Holdings SA (NYSE: CPA) - consensus EPS $1.09
Core Laboratories (NYSE: CLB) - consensus EPS $1.20
Corporate Office Properties Trust (NYSE: OFC) - consensus EPS $0.11
DENTSPLY International Inc. (NASDAQ: XRAY) - consensus EPS $0.49
Echelon Corporation (NASDAQ: ELON) - consensus loss $0.17
Education Management Corporation (NASDAQ: EDMC) - consensus EPS $0.39
eLoyalty (NASDAQ: ELOY) - consensus EPS $0.03
Everest Re Group, Ltd. (NYSE: RE) - consensus EPS $3.38
GLU Mobile Inc. (NASDAQ: GLUU) - consensus EPS $0.01
Highwoods Properties (NYSE: HIW) - consensus EPS $0.59
Insight Enterprises, Inc. (NASDAQ: NSIT) - consensus EPS $0.20
Kona Grill Inc. (NASDAQ: KONA) - consensus loss $0.16
Longtop Financial Technologies Limited (NYSE: LFT) - consensus EPS $0.44
LoopNet, Inc. (NASDAQ: LOOP) - consensus EPS $0.06
Masco (NYSE: MAS) - no Street consensus
PartnerRe Ltd. (NYSE: PRE) - consensus EPS $2.81
Penn Virginia (NYSE: PVA) - consensus loss $0.10
Penn Virginia GP Holdings LP (NYSE: PVG) - consensus EPS $0.28
Plains All American Pipeline (NYSE: PAA) - consensus EPS $0.70
Prudential Financial, Inc. (NYSE: PRU) - consensus EPS $1.11
Support.com, Inc (NASDAQ: SPRT) - consensus loss $0.10
Taleo Corporation (NASDAQ: TLEO) - consensus EPS $0.17
The Allstate Corporation (NYSE: ALL) - consensus EPS $1.01
Torchmark (NYSE: TMK) - consensus EPS $1.44
Transatlantic Holdings, Inc. (NYSE: TRH) - consensus EPS $1.83
Vale S.A. (NASDAQ: VALE) - consensus EPS $0.32

Subscribe to EasyStockAlerts and get real-time e-mail alerts when news hits your stocks!

Unusual 11 Mid-Day Movers 2/9: ACLI, CLWT, CTIC, NBG, ECPG Higher; TRID, MGAM, CONN, TMRK Lower Feb 9, 2010 01:31PM

American Commercial Lines Inc. (NASDAQ: ACLI) 25.7% HIGHER; reports Q4 EPS of $1.09 including items, which may not compare to the analyst estimate of $0.06. Revenue for the quarter was $226.9 million, which compares to the estimate of $222.49 million.

Euro Tech Holdings Company Limited (NASDAQ: CLWT) 20.7% HIGHER; today announced that its subsidiary, Yixing PACT Environmental Technology Company Ltd. has recently been awarded a contract by a Korean stainless steel company, worth about US$ 3.8 million. Click here for the full report.

Cell Therapeutics, Inc. (NASDAQ: CTIC) 19.1% HIGHER; announced today that the US FDA informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application. The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.

National Bank of Greece (NYSE: NBG) 18.1% HIGHER; after several days of debt worries, today traders seem to be betting that this issue will eventually be resolved. Reports came out saying Germany was considering giving aid to Greece, however, a government spokesman debunked these rumors.

Encore Capital Group, Inc. (Nasdaq: ECPG) 17.3% HIGHER; reports Q4 EPS of $0.34, veruss the analyst estimate of $0.42 and compared to a loss of $0.09 in the same quarter last year. Revenue for the quarter was $81.55 million, which compares to the estimate of $88.17 million.

Trident Microsystems (NASDAQ: TRID) 17.1% LOWER; reports Q2 adjusted loss of $0.22, versus the analyst estimate of ($0.18). Revenue for the quarter was $31.9 million, which compares to the estimate of $32.75 million.

UAL Corp. (Nasdaq: UAUA) 16.1% HIGHER; United Air reported its preliminary consolidated traffic results for January 2010. Total consolidated revenue passenger miles increased in January by 2.4% on a decrease of 2.0% in available seat miles compared with the same period in 2009. This resulted in a reported January 2010 consolidated passenger load factor of 78.5%, an increase of 3.4 points compared to 2009.

Multimedia Games Inc. (Nasdaq: MGAM) 16% LOWER; reports Q4 loss of $0.15, 7 cents worse than the analyst estimate of ($0.08). Revenue for the quarter was $26.3 million, which compares to the estimate of $29.70 million.

Conn’s, Inc. (NASDAQ: CONN) 15.5% LOWER; today announced net sales for the quarter ended January 31, 2010, of $171.0 million, decreased $74.5 million, or 30.3%, after achieving a 22.3% increase in the same quarter of the prior fiscal year. Click here for the full report.

Terremark Worldwide, Inc. (NASDAQ: TMRK) 15.3% LOWER; reports a Q3 loss of $0.13, 5 cents worse than the analyst estimate of ($0.08). Revenue for the quarter was $74.3 million, which compares to the estimate of $75.07 million. Sees Q4 revenues to range from $80.1 million to $85.1 million and EBITDA, as adjusted, to range from $25.4 million to $30.4 million. (Revenue consensus is $80.84 million) Sees FY10, EBITDA, as adjusted, of $80.0 million to $85.0 million and revenues to range between $290.0 million to $295.0 million. (Revenue consensus is $291.44 million) Sees FY11 revenues between $335.0 million and $340.0 million and EBITDA, as adjusted, to range from $95.0 million to $100.0 million. (Revenue consensus is $348.59 million) The stock was also downgraded at Jefferies and Craig-Hallum.

Toreador Resources Corporation (NASDAQ: TRGL) 14.6% LOWER; announced today that it has priced an underwritten public offering of 3 million shares of common stock at a public offering price of $8.50 per share. The offering is expected to close on February 12, 2010, subject to customary closing conditions.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Notable ETF Movers for 02/09: XME, OIH, MOO Up; UNG, IRY, UUP Lower Feb 9, 2010 12:27PM

Notable ETF movers for 02/09:

Advancers

• SPDR S&P Metals & Mining (NYSE: XME) down 4.52 % to $47.68. Shares surge on a lower dollar and a strong earnings report from Alpha Natural Resources (NYSE: ANR) topping EPS views by 6 cents. Metal futures across the board are also up.
  
  
• Oil Services HOLDRs (NYSE: OIH) up 3.61% to $119.15. As future of oil are up on a lower dollar, Nabors (NYSE: NBR) is forecasting that their results will top EPS estimates of $0.16, albeit modestly.
  
  
• Market Vectors Agribusiness ETF (NYSE: MOO) is mooooving up 3.70% to $41.75. Agriculture futures are up on reports from the USDA that due to unforseen frost in Florida due to chillier temps this year, the production report for February is revised down 6 million 90-pound boxes of oranges. Also, of course, the weaker dollar.
  
  Receders
  
  
  
  • United States Natural Gas (NYSE: UNG) down 2.45% to $9.57. Shares of the ETF are down today as colder temperatures are forecasted, but gas stores are up. For the week ended January 29, 2010, there was 2.406 trillion cubic feet available, a 9% increase Y/Y and 6.6% above the five-year average.
    
    
  • iShares Dow Jones US Real Estate (NYSE: IYR) down 1.01% to $42.15. Top holding Annaly Capital Management, Inc. (NYSE: NLY) announced the issuance of $500M in convertible senior notes, singaling the need to raise capital.
    
    
  • PowerShares DB US Dollar Index Bullish (NYSE: UUP) down 0.42% to $23.54. The dollar is ebbing as concerns over Greek debt seem to be easing, fortifying the move into the Euro by many investors.
    
    

Notable Mergers and Acquisitions of the Day 02/09: VOLC, MORN Feb 9, 2010 10:14AM

• Volcano Corporation (NASDAQ: VOLC) announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical. Volcano became the exclusive global distributor of the Xtract™ catheter in May 2009. This acquisition reinforces Volcano's dedication to build a strategic portfolio of diagnostic and therapeutic tools to help patients with coronary artery disease at all levels of complexity, including acute myocardial infarction (AMI) or heart attacks.
  
  The Xtract™ thrombus aspiration catheter supports the care of ST Segment Elevation Myocardial Infarction (STEMI). The main cause of heart attacks is a plaque rupture in one of the main coronary arteries. Plaque builds up in the arterial wall and ruptures, which can generate a blood clot or thrombus that blocks blood flow and deprives the heart muscle of oxygen. As long as the clot subsists, cells of the heart muscle will continue to die and worsen the patient's condition. The Xtract™ aspiration catheter, with its patented, large single lumen design, circular right-angle tip, and curved directional distal segment, delivers fast and powerful clot removal to help re-establish blood flow quickly. The product line includes two sizes, with the larger size model offering the largest aspiration lumen of any aspiration catheter, for effective and efficient clot extractions.
  
  "Volcano is excited to fortify its commitment to be the leading and most-trusted partner for physicians when addressing patients with complex disease states that require thrombus aspiration," said Scott Huennekens, President and Chief Executive Officer of Volcano. "Since we began to distribute the Xtract™ catheter last year, it has been well-received by the interventional cardiology community. Consistent with our drive to continuously improve our product offerings, we now have control over the product and rights to the design, and will be able to directly build upon the feedback we have received from our customers on how to further improve upon our unique approach to thrombus aspiration."
  
  As a result of the strength of recent clinical studies, a new recommendation acknowledging that the use of aspiration thrombectomy is reasonable to treat STEMI was a key change in the December 2009 update to the STEMI and percutaneous coronary intervention (PCI) guidelines. These guidelines for treating coronary disease and heart attacks using PCI were issued by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI). "There are three clinical studies cited in the guidelines – TAPAS, EXPIRA, and ATTEMPT - that clearly demonstrate the potential benefit of using aspiration thrombectomy in STEMI patients," said Dr. Matthew Price, Director of the Cardiac Catheterization Laboratory at Scripps Clinic and Director of Interventional Cardiology Research for Scripps Genomic Medicine. "In the TAPAS study, with aspiration versus PCI alone, there was a 46% reduction in cardiac death at 1 year. In the EXPIRA study, there was no cardiac death in the PCI only group versus 6.5% death at 2 years. In the ATTEMPT study, which was a large pooled analysis of randomized trials, there was a 34% reduction in mortality even with the use of IIb/IIa inhibitors. In addition to better clinical outcomes, these studies also showed better procedural results with respect to Myocardial Blush Grade and resolution of ST Segment Elevation Resolution."
  
  "Aspiration has really been a game-changer with respect to how we treat a STEMI in the cath lab," continued Dr. Price. "Starting with aspiration rather than balloon angioplasty prevents distal embolization and reflow. Furthermore, by re-establishing blood flow beyond the initial clot, the rest of the vessel becomes visible so we can better diagnose the location and severity of the vessel blockage and optimize stent placement."
  
  "Volcano could not be more pleased about the new recommendation from the ACC, AHA, and SCAI that aspiration thrombectomy, the procedure for which the Xtract™ device is uniquely designed, is reasonable in primary PCI for STEMI," noted Vince Burgess, Group President of Advanced Imaging Systems at Volcano. "This acquisition of the Xtract™ device line underscores how Volcano strives to be strategically ahead of the curve by providing physicians with the right technologies supported by the most impactful clinical data."
  
  "Just like our previous acquisitions of CardioSpectra, Novelis, and Axsun, we are excited to add another innovative technology to the comprehensive suite of tools we are building to support physicians, regardless of how complex the disease state they address might be," added Burgess. "Although our core IVUS and FM products are used in both routine and complex clinical scenarios, Volcano is continuing to execute on our therapeutic strategy by investing in products and clinical studies aimed at procedures whose outcomes have the most room for improvement. These include AMI, CTO (Chronic Total Occlusion) and Bifurcation lesions. The acquisition of the Xtract™ product line is yet another example of our commitment to that strategy."
  
  
• Morningstar, Inc. (NASDAQ: MORN) today announced it has acquired the Footnoted business of Financial Fineprint Inc., a privately held firm based in Peekskill, N.Y. The acquisition includes the Footnoted.org website and the Footnoted Pro service. Terms were not disclosed.

To see all the Mergers & Acquisitions for today in real-time go to http://www.streetinsider.com/Mergers+and+Acquisitions